Clasp founder and CEO Tess Michaels joins Wealth! to discuss her mission of connecting students with employers who will invest in their education and careers. "I actually founded Clasp from a ...

- CLSP-1025 targets the most common p53 mutation, a key oncogenic driver associated with multiple types of solid tumors, including gastrointestinal, lung, and gynecological cancers - Clasp's pHLAre™ ...

Clasp’s model helps healthcare employers commit to clinicians before graduation and ties student loan repayment to employee tenure, replacing transactional sign-on bonuses with retention-based ...

Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of drug called a T cell engager. These drugs bind to a cancer cell and a T cell simultaneously, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company connects healthcare ...

- Clasp's pHLAre™ platform is optimized for tumor-specific antigens, with the potential to yield safer and more effective precision immunotherapies - Preclinical data presented at the 2025 American ...